Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.

Abstract

Apatinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatment of patients with non-small-cell lung cancer and gastric cancer in China. In this study, we determined the effect of apatinib on the interaction of specific antineoplastic compounds with P-glycoprotein (ABCB1), multidrug resistance protein 1… (More)
DOI: 10.1158/0008-5472.CAN-10-0111

Topics

Cite this paper

@article{Mi2010ApatinibR, title={Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.}, author={Yan-jun Mi and Yong-ju Liang and Hong-Bing Huang and Hong-yun Zhao and Chung-Pu Wu and Fang Wang and Li-yang Tao and Chuan-zhao Zhang and Chun-Ling Dai and Amit Mani Kumar Tiwari and Xiao-xu Ma and Kenneth Kin-Wah To and Suresh V Ambudkar and Zhe-Sheng Chen and Li-wu Fu}, journal={Cancer research}, year={2010}, volume={70 20}, pages={7981-91} }